Wolverine Trading’s scPharmaceuticals SCPH Stock Holding History

Wolverine Trading’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-19,726	Closed	-$124K	–	5191
2023 Q4	$124K	Buy	+19,726	New	+$113K	﹤0.01%	4050
2022 Q4	–	Sell	-23,282	Closed	-$141K	–	4906
2022 Q3	$141K	Buy	23,282 +9,512	+69%	+$50.8K	﹤0.01%	3782
2022 Q2	$68K	Buy	+13,770	New	+$68.1K	﹤0.01%	3970

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Wolverine Trading's SCPH Position: Q1 2024 in Review

Wolverine Trading sold out of scPharmaceuticals (SCPH) in Q1 2024, closing a stake of 19,726 shares — an estimated $124K sold.

Wolverine Trading first reported a position in SCPH in Q2 2022 and held it in 3 quarters. The position peaked at $141K in Q3 2022. 76 funds tracked by Wall St. Rank hold SCPH as of Q1 2024.

Wolverine Trading reported no remaining scPharmaceuticals position as of Q1 2024 after selling out during the quarter.
Wolverine Trading sold 19,726 scPharmaceuticals shares in Q1 2024, an estimated $124K.
Wolverine Trading first reported a position in scPharmaceuticals in Q2 2022 and held it in 3 quarters.
Wolverine Trading's scPharmaceuticals position peaked at $141K in Q3 2022.
76 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2024.

Based on Wolverine Trading's 13F filing for Q1 2024, filed 15 May 2024.